Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Benitec Biopharma Ltd ADR (BNTC)

Benitec Biopharma Ltd ADR (BNTC)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
12.63 +0.69 (+5.78%) 04/11/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 12.63 unch (unch) 16:01 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
11.49
Day High
12.87
Open 11.88
Previous Close 11.94 11.94
Volume 54,500 54,500
Avg Vol 69,590 69,590
Stochastic %K 32.19% 32.19%
Weighted Alpha +70.55 +70.55
5-Day Change +0.31 (+2.52%) +0.31 (+2.52%)
52-Week Range 4.75 - 16.90 4.75 - 16.90
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 296,186
  • Shares Outstanding, K 23,451
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,750 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.26
  • Low Estimate -0.42
  • Prior Year -1.64
  • Growth Rate Est. (year over year) +78.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.50 +20.29%
on 04/07/25
Period Open: 13.29
16.90 -25.27%
on 03/21/25
-0.66 (-4.97%)
since 03/11/25
3-Month
9.70 +30.21%
on 02/13/25
Period Open: 11.00
16.90 -25.27%
on 03/21/25
+1.63 (+14.82%)
since 01/10/25
52-Week
4.75 +165.89%
on 04/16/24
Period Open: 6.23
16.90 -25.27%
on 03/21/25
+6.40 (+102.73%)
since 04/11/24

Most Recent Stories

More News
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

BNTC : 12.63 (+5.78%)
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

BNTC : 12.63 (+5.78%)
Benitec - Another Biopharma Rocket

Summary Benitec Biopharma (BNTC) shows strong technical indicators with 100% buy signals, a 127.84+ Weighted Alpha, and a 190.67% gain in the last year. The stock is above its 20, 50, and 100-day moving...

BNTC : 12.63 (+5.78%)
Benitec Biopharma to Participate in Upcoming Conferences in March

BNTC : 12.63 (+5.78%)
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

BNTC : 12.63 (+5.78%)
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference

BNTC : 12.63 (+5.78%)
Benitec Biopharma to Participate in Upcoming Conferences in January and February

BNTC : 12.63 (+5.78%)
Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock

One stock that might be an intriguing choice for investors right now is Benitec Biopharma Inc. BNTC. This is because this security in the Manufacturing - Electronics space is seeing solid earnings estimate...

BNTC : 12.63 (+5.78%)
Benitec Biopharma Inc. to Participate in Upcoming Investor Conferences in December 2024

Benitec Biopharma will participate in investor conferences on December 4 and December 12, 2024, in New York.Quiver AI SummaryBenitec Biopharma Inc., a biotechnology company based in Hayward, California,...

BNTC : 12.63 (+5.78%)
Benitec Biopharma to Participate in Upcoming Investor Conferences in December

BNTC : 12.63 (+5.78%)

Business Summary

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B,...

See More

Key Turning Points

3rd Resistance Point 14.55
2nd Resistance Point 13.71
1st Resistance Point 13.17
Last Price 12.63
1st Support Level 11.79
2nd Support Level 10.95
3rd Support Level 10.41

See More

52-Week High 16.90
Last Price 12.63
Fibonacci 61.8% 12.26
Fibonacci 50% 10.82
Fibonacci 38.2% 9.39
52-Week Low 4.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar